Other Events ·
Alpha Tau Medical Ltd. announced on August 31, 2026, that it has completed patient enrollment in its multicenter…
DRTSAlpha Tau Medical Ltd.
Alpha Tau Medical Ltd. announced on August 31, 2026, that it has completed patient enrollment in its multicenter IMPACT pilot study evaluating Alpha DaRT for newly diagnosed unresectable pancreatic cancer. The trial expanded enrollment three times from an initial target of 12 to a total of 48 treated patients across the United States, Canada, and Israel. Initial data is targeted for release in early 2027 to inform the design of a planned pivotal study. Alpha Tau Medical Ltd. operates in the oncology therapeutics industry, focusing on the research and development of alpha-radiation cancer therapy.